Bafna to launch olmesartan in Sri Lanka
This article was originally published in Scrip
Bafna Pharmaceuticals of India is planning to launch the antihypertensive olmesartan medoxomil (branded as Olmebaf) in Sri Lanka early next year. The company expects to sell the product directly through its own front-end there. Olmesartan medoxomil and its combination with hydrochlorothiazide have been approved by the Drugs Controller General of India since 2005. Bafna said that the incidence of ischaemic heart disease and cerebrovascular disease in Sri Lanka has been on the rise over the past four decades and is similar to that of the developed world. The company has applied for registration of its product in a few more Asian countries. Chennai-based Bafna manufactures pharmaceutical formulations of betalactum and non–betalactum products and has more than 65 products registered in Sri Lanka, Ukraine, Laos and Ghana.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.